NUT Carcinoma Testing: Beyond Standard DNA – A Better Approach
- Jia Luo, co-senior author, thoracic oncologist at the Lowe Center for Thoracic Oncology, Dana-Farber
Study Paves path to Improved Diagnosis and Treatment of NUT Carcinoma
Table of Contents
New research highlights the most effective methods for identifying this aggressive cancer, opening doors for better patient outcomes.
Dr. Jia Luo, co-senior author, thoracic oncologist at the Lowe Center for Thoracic Oncology, Dana-Farber
NUT carcinoma is a rare and aggressive form of squamous cell cancer that can affect the lungs, head, and neck. It is notably challenging to diagnose, often striking younger individuals with little to no history of smoking. The prognosis for patients with NUT carcinoma is grim, with a median survival of just 6.7 months. The defining characteristic of this cancer is the presence of gene fusions involving the Nutm1 gene, were errors in the genome cause two genes to fuse, leading to the production of a faulty protein that drives cancer growth.
Advancing Diagnostic accuracy for NUT Carcinoma
Recognizing the critical need for more reliable diagnostic tools, Dr. Jia Luo, a thoracic oncologist at the Lowe Center for Thoracic Oncology at dana-Farber, and co-senior author Dr. Christopher French from Brigham and Women’s hospital, led a comprehensive study to pinpoint the most effective methods for detecting these crucial gene fusions.Their research aimed to establish a definitive diagnostic pathway for NUT carcinoma.
The team meticulously examined the molecular testing results from 116 NUT carcinoma tumors. These samples had undergone a variety of panel tests, including next-generation DNA sequencing, circulating tumor DNA (ctDNA) testing, and specialized tests designed to identify gene fusions.
comparing Diagnostic Test Performance
The study’s findings revealed significant disparities in the effectiveness of different diagnostic approaches. While DNA sequencing and ctDNA testing detected NUT fusions in less than 25 percent of cases, other methods proved far more successful. Specifically,NUT immunohistochemistry (IHC),RNA fusion testing,and Nutm1 FISH (fluorescence in situ hybridization) testing demonstrated much higher reliability,detecting NUT carcinoma fusions in 100 percent,84 percent,and 92 percent of cases,respectively.
“These findings warrant immediate change to the diagnostic workflow for patients with suspected NUT carcinoma,” stated Dr. Luo. The research strongly suggests that a combined approach, incorporating DNA testing and RNA fusion testing simultaneously, is essential for accurate diagnosis. This strategy is already employed in the diagnosis of other cancers where gene fusion identification is critical.
Uncovering Potential Therapeutic targets
Beyond diagnostic accuracy, the study also delved into the broader molecular landscape of NUT carcinoma, cataloging other mutations present in the tumors. The research found that over half of the NUT carcinoma cases did not harbor a secondary cancer-associated gene mutation. Though, a notable subset of cases did present with additional mutations.
These additional mutations were primarily found in genes associated with epigenetic regulation, cell cycle control, and DNA repair pathways. Dr. Luo and her colleagues are now initiating laboratory studies to investigate whether targeting these specific mutations could offer therapeutic benefits to patients.
“This study characterized the common mutations seen in NUT carcinoma, which will help researchers develop future effective combination treatments,” Dr. Luo concluded. By improving diagnostic precision and identifying potential new therapeutic avenues, this research represents a significant step forward in the fight against NUT carcinoma, offering hope for improved patient outcomes.
Source: Dana-Farber Cancer Institute
Journal Reference: Kim, JJ, et al. (2025) Molecular characterization of NUT carcinoma: a report from the NUT carcinoma registry. Clinical Cancer Research*. doi.org/10.1158/1078-0432.CCR-25-1071